Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

Today, we are powering and de-risking drug discovery pipelines with TileDB as the foundation ... Prior to joining Alexion in 2015, George was employed by Merck & Co., Inc. for 25 years in IT positions ...

However, that is less true for large-cap stocks like Merck and Bristol-Myers. Still, it’s important to understand why ...

Kindeva Drug Delivery, a global CDMO and drug delivery expert, has appointed Prakash Pandian as Chief Information Officer ...